Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 30, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 744,450 Ordinary Shares of 25 pence each.
- Purchase Date: November 30, 2012.
- Price Range: Highest price paid was 1,347.0 pence per share; lowest price paid was 1,337.5 pence per share.
- Treasury Holdings: 490,140,427 shares held in Treasury (9.08% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury shares represent 9.98% of total voting rights.
- Shares in Issue: 4,909,525,424 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 744,450 shares purchased on November 30, 2012. This transaction increased the proportion of shares held in Treasury relative to total voting rights to 9.98%.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase and does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (490,140,427) against the company's latest annual report.
- Confirm the calculation of total voting rights (9.98% held in Treasury) for disclosure threshold assessments.
- Check the price paid per share (1,337.5 to 1,347.0 pence) against market trading data for November 30, 2012.
- Ensure the 744,450 shares purchased are reflected as cancelled in subsequent capitalization tables.